Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Shionogi Inc.
National Cancer Institute (NCI)
Genelux Corporation
Coherus Oncology, Inc.
Rutgers, The State University of New Jersey
BeOne Medicines
BeOne Medicines
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Lepu Biopharma Co., Ltd.
National Cancer Institute (NCI)
Bristol-Myers Squibb
Hoffmann-La Roche
Roswell Park Cancer Institute
Seagen Inc.
St. Jude Children's Research Hospital
Centre Hospitalier Universitaire de Besancon
Incyte Corporation
N.N. Alexandrov National Cancer Centre
N.N. Alexandrov National Cancer Centre
Shanghai JMT-Bio Inc.
Centre Oscar Lambret
Seagen Inc.
Hoffmann-La Roche
Seagen Inc.
Revolution Medicines, Inc.
Delcath Systems Inc.
Janssen Research & Development, LLC
Pfizer
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Whitehawk Therapeutics, Inc.
BioNTech SE
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Nanjing Leads Biolabs Co.,Ltd
Hoffmann-La Roche
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Federation Francophone de Cancerologie Digestive